---
document_datetime: 2025-12-02 04:59:51
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/mulpleo.html
document_name: mulpleo.html
version: success
processing_time: 0.0864998
conversion_datetime: 2025-12-23 23:54:34.936173
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Mulpleo (previously Lusutrombopag Shionogi)

[RSS](/en/individual-human-medicine.xml/67180)

##### Authorised

This medicine is authorised for use in the European Union

lusutrombopag Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Mulpleo (previously Lusutrombopag Shionogi)](#news-on)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Mulpleo is a medicine used to prevent excessive bleeding in adults with thrombocytopenia due to long-standing liver disease. Patients with thrombocytopenia have reduced number of platelets (components in the blood that help it to clot), which can cause excessive bleeding.

The medicine is for use in patients having an invasive procedure (a medical procedure that involves cutting into or puncturing the skin or inserting instruments into the body).

Mulpleo contains the active substance lusutrombopag.

Expand section

Collapse section

## How is Mulpleo used?

Mulpleo is available as 3 mg tablets. The medicine can only be obtained with a prescription.

Treatment with Mulpleo should start at least 8 days before the procedure and the recommended dose is 1 tablet daily for 7 days.

For more information about using Mulpleo, see the package leaflet or contact your doctor or pharmacist.

## How does Mulpleo work?

In the body, a hormone called thrombopoietin stimulates the production of platelets by attaching to receptors (targets) in the bone marrow. The active substance in Mulpleo, lusutrombopag, attaches to the same receptors as thrombopoietin, helping to increase the platelet count.

## What benefits of Mulpleo have been shown in studies?

In two main studies involving adults with low levels of platelets due to long-standing liver disease, Mulpleo increased platelet count before an invasive procedure and reduced the need for transfusions.

The first study, involving 96 adults, found that 79% of patients who took Mulpleo did not require a transfusion of platelets before their procedure, compared with 13% of patients who received placebo (a dummy treatment). The second study involving 215 adults found that 65% of patients who took Mulpleo did not require platelet transfusion before their procedure, compared with 29% of patients who received placebo.

## What are the risks associated with Mulpleo?

Unwanted effects that occurred in studies involving patients taking Mulpleo were headache, nausea (feeling sick), portal vein thrombosis (a blockage in the blood vessel that carries blood from the intestines to the liver) and rash. Similar effects occurred in patients receiving placebo.

For more information on the side effects and restrictions of Mulpleo, see the package leaflet.

## Why is Mulpleo authorised in the EU?

Studies have found that Mulpleo increases platelet count, thereby lowering the risk of excessive bleeding during or after an invasive procedure and reducing the need for transfusing platelets. Unwanted effects that occurred in studies are thought to result from patients' medical condition and the nature of the invasive procedure for which Mulpleo was used.

The European Medicines Agency decided that Mulpleo's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Mulpleo?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Mulpleo have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Mulpleo are continuously monitored. Side effects reported with Mulpleo are carefully evaluated and any necessary action taken to protect patients.

## Other information about Mulpleo

Mulpleo received a marketing authorisation valid throughout the EU on 18 February 2019.

Mulpleo : EPAR - Medicine overview

Reference Number: EMA/553072/2019

English (EN) (74.75 KB - PDF)

**First published:** 14/03/2019

**Last updated:** 20/11/2019

[View](/en/documents/overview/mulpleo-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-522)

български (BG) (100.86 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

20/11/2019

[View](/bg/documents/overview/mulpleo-epar-medicine-overview_bg.pdf)

español (ES) (74.18 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

20/11/2019

[View](/es/documents/overview/mulpleo-epar-medicine-overview_es.pdf)

čeština (CS) (96.77 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

20/11/2019

[View](/cs/documents/overview/mulpleo-epar-medicine-overview_cs.pdf)

dansk (DA) (73.12 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

20/11/2019

[View](/da/documents/overview/mulpleo-epar-medicine-overview_da.pdf)

Deutsch (DE) (74.56 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

20/11/2019

[View](/de/documents/overview/mulpleo-epar-medicine-overview_de.pdf)

eesti keel (ET) (73.17 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

20/11/2019

[View](/et/documents/overview/mulpleo-epar-medicine-overview_et.pdf)

ελληνικά (EL) (107.6 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

20/11/2019

[View](/el/documents/overview/mulpleo-epar-medicine-overview_el.pdf)

français (FR) (74.35 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

20/11/2019

[View](/fr/documents/overview/mulpleo-epar-medicine-overview_fr.pdf)

hrvatski (HR) (92.25 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

20/11/2019

[View](/hr/documents/overview/mulpleo-epar-medicine-overview_hr.pdf)

italiano (IT) (73.49 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

20/11/2019

[View](/it/documents/overview/mulpleo-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (95.86 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

20/11/2019

[View](/lv/documents/overview/mulpleo-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (95.95 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

20/11/2019

[View](/lt/documents/overview/mulpleo-epar-medicine-overview_lt.pdf)

magyar (HU) (92.92 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

20/11/2019

[View](/hu/documents/overview/mulpleo-epar-medicine-overview_hu.pdf)

Malti (MT) (97 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

20/11/2019

[View](/mt/documents/overview/mulpleo-epar-medicine-overview_mt.pdf)

Nederlands (NL) (73.66 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

20/11/2019

[View](/nl/documents/overview/mulpleo-epar-medicine-overview_nl.pdf)

polski (PL) (97.55 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

20/11/2019

[View](/pl/documents/overview/mulpleo-epar-medicine-overview_pl.pdf)

português (PT) (74.15 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

20/11/2019

[View](/pt/documents/overview/mulpleo-epar-medicine-overview_pt.pdf)

română (RO) (94.31 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

20/11/2019

[View](/ro/documents/overview/mulpleo-epar-medicine-overview_ro.pdf)

slovenčina (SK) (95.54 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

20/11/2019

[View](/sk/documents/overview/mulpleo-epar-medicine-overview_sk.pdf)

slovenščina (SL) (89.49 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

20/11/2019

[View](/sl/documents/overview/mulpleo-epar-medicine-overview_sl.pdf)

Suomi (FI) (73.05 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

20/11/2019

[View](/fi/documents/overview/mulpleo-epar-medicine-overview_fi.pdf)

svenska (SV) (73.4 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

20/11/2019

[View](/sv/documents/overview/mulpleo-epar-medicine-overview_sv.pdf)

Lusutrombopag Shionogi : EPAR - Risk-management-plan summary

English (EN) (73.06 KB - PDF)

**First published:** 14/03/2019

[View](/en/documents/rmp-summary/lusutrombopag-shionogi-epar-risk-management-plan-summary_en.pdf)

## Product information

Mulpleo : EPAR - Product information

English (EN) (602.58 KB - PDF)

**First published:** 14/03/2019

**Last updated:** 16/02/2024

[View](/en/documents/product-information/mulpleo-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-686)

български (BG) (703.39 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

16/02/2024

[View](/bg/documents/product-information/mulpleo-epar-product-information_bg.pdf)

español (ES) (636.47 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

16/02/2024

[View](/es/documents/product-information/mulpleo-epar-product-information_es.pdf)

čeština (CS) (682.47 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

16/02/2024

[View](/cs/documents/product-information/mulpleo-epar-product-information_cs.pdf)

dansk (DA) (605.81 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

16/02/2024

[View](/da/documents/product-information/mulpleo-epar-product-information_da.pdf)

Deutsch (DE) (646.78 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

16/02/2024

[View](/de/documents/product-information/mulpleo-epar-product-information_de.pdf)

eesti keel (ET) (615.65 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

16/02/2024

[View](/et/documents/product-information/mulpleo-epar-product-information_et.pdf)

ελληνικά (EL) (663.32 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

16/02/2024

[View](/el/documents/product-information/mulpleo-epar-product-information_el.pdf)

français (FR) (660.23 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

16/02/2024

[View](/fr/documents/product-information/mulpleo-epar-product-information_fr.pdf)

hrvatski (HR) (658.33 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

16/02/2024

[View](/hr/documents/product-information/mulpleo-epar-product-information_hr.pdf)

íslenska (IS) (630.1 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

16/02/2024

[View](/is/documents/product-information/mulpleo-epar-product-information_is.pdf)

italiano (IT) (653.24 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

16/02/2024

[View](/it/documents/product-information/mulpleo-epar-product-information_it.pdf)

latviešu valoda (LV) (681.79 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

16/02/2024

[View](/lv/documents/product-information/mulpleo-epar-product-information_lv.pdf)

lietuvių kalba (LT) (648.92 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

16/02/2024

[View](/lt/documents/product-information/mulpleo-epar-product-information_lt.pdf)

magyar (HU) (649.53 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

16/02/2024

[View](/hu/documents/product-information/mulpleo-epar-product-information_hu.pdf)

Malti (MT) (638.98 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

16/02/2024

[View](/mt/documents/product-information/mulpleo-epar-product-information_mt.pdf)

Nederlands (NL) (633.99 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

16/02/2024

[View](/nl/documents/product-information/mulpleo-epar-product-information_nl.pdf)

norsk (NO) (600.15 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

16/02/2024

[View](/no/documents/product-information/mulpleo-epar-product-information_no.pdf)

polski (PL) (649.94 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

16/02/2024

[View](/pl/documents/product-information/mulpleo-epar-product-information_pl.pdf)

português (PT) (651.69 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

16/02/2024

[View](/pt/documents/product-information/mulpleo-epar-product-information_pt.pdf)

română (RO) (661.5 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

16/02/2024

[View](/ro/documents/product-information/mulpleo-epar-product-information_ro.pdf)

slovenčina (SK) (681.88 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

16/02/2024

[View](/sk/documents/product-information/mulpleo-epar-product-information_sk.pdf)

slovenščina (SL) (651.95 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

16/02/2024

[View](/sl/documents/product-information/mulpleo-epar-product-information_sl.pdf)

Suomi (FI) (624.01 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

16/02/2024

[View](/fi/documents/product-information/mulpleo-epar-product-information_fi.pdf)

svenska (SV) (622.71 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

16/02/2024

[View](/sv/documents/product-information/mulpleo-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IAIN/0017/G 05/01/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Mulpleo (previously Lusutrombopag Shionogi) : EPAR - All authorised presentations

English (EN) (15.38 KB - PDF)

**First published:** 14/03/2019

**Last updated:** 29/08/2019

[View](/en/documents/all-authorised-presentations/mulpleo-previously-lusutrombopag-shionogi-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-435)

български (BG) (68.35 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

29/08/2019

[View](/bg/documents/all-authorised-presentations/mulpleo-previously-lusutrombopag-shionogi-epar-all-authorised-presentations_bg.pdf)

español (ES) (29.99 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

29/08/2019

[View](/es/documents/all-authorised-presentations/mulpleo-previously-lusutrombopag-shionogi-epar-all-authorised-presentations_es.pdf)

čeština (CS) (42 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

29/08/2019

[View](/cs/documents/all-authorised-presentations/mulpleo-previously-lusutrombopag-shionogi-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (29.73 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

29/08/2019

[View](/da/documents/all-authorised-presentations/mulpleo-previously-lusutrombopag-shionogi-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (29.85 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

29/08/2019

[View](/de/documents/all-authorised-presentations/mulpleo-previously-lusutrombopag-shionogi-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (29.81 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

29/08/2019

[View](/et/documents/all-authorised-presentations/mulpleo-previously-lusutrombopag-shionogi-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (67.71 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

29/08/2019

[View](/el/documents/all-authorised-presentations/mulpleo-previously-lusutrombopag-shionogi-epar-all-authorised-presentations_el.pdf)

français (FR) (29.8 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

29/08/2019

[View](/fr/documents/all-authorised-presentations/mulpleo-previously-lusutrombopag-shionogi-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (46.05 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

29/08/2019

[View](/hr/documents/all-authorised-presentations/mulpleo-previously-lusutrombopag-shionogi-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (29.67 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

29/08/2019

[View](/is/documents/all-authorised-presentations/mulpleo-previously-lusutrombopag-shionogi-epar-all-authorised-presentations_is.pdf)

italiano (IT) (29.81 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

29/08/2019

[View](/it/documents/all-authorised-presentations/mulpleo-previously-lusutrombopag-shionogi-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (65.79 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

29/08/2019

[View](/lv/documents/all-authorised-presentations/mulpleo-previously-lusutrombopag-shionogi-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (61.88 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

29/08/2019

[View](/lt/documents/all-authorised-presentations/mulpleo-previously-lusutrombopag-shionogi-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (66.34 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

29/08/2019

[View](/hu/documents/all-authorised-presentations/mulpleo-previously-lusutrombopag-shionogi-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (65.67 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

29/08/2019

[View](/mt/documents/all-authorised-presentations/mulpleo-previously-lusutrombopag-shionogi-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (29.74 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

29/08/2019

[View](/nl/documents/all-authorised-presentations/mulpleo-previously-lusutrombopag-shionogi-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (29.76 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

29/08/2019

[View](/no/documents/all-authorised-presentations/mulpleo-previously-lusutrombopag-shionogi-epar-all-authorised-presentations_no.pdf)

polski (PL) (42.62 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

29/08/2019

[View](/pl/documents/all-authorised-presentations/mulpleo-previously-lusutrombopag-shionogi-epar-all-authorised-presentations_pl.pdf)

português (PT) (25.42 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

29/08/2019

[View](/pt/documents/all-authorised-presentations/mulpleo-previously-lusutrombopag-shionogi-epar-all-authorised-presentations_pt.pdf)

română (RO) (65.59 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

29/08/2019

[View](/ro/documents/all-authorised-presentations/mulpleo-previously-lusutrombopag-shionogi-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (42.36 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

29/08/2019

[View](/sk/documents/all-authorised-presentations/mulpleo-previously-lusutrombopag-shionogi-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (41.67 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

29/08/2019

[View](/sl/documents/all-authorised-presentations/mulpleo-previously-lusutrombopag-shionogi-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (25.18 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

29/08/2019

[View](/fi/documents/all-authorised-presentations/mulpleo-previously-lusutrombopag-shionogi-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (29.7 KB - PDF)

**First published:**

14/03/2019

**Last updated:**

29/08/2019

[View](/sv/documents/all-authorised-presentations/mulpleo-previously-lusutrombopag-shionogi-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Mulpleo (previously Lusutrombopag Shionogi) Active substance Lusutrombopag International non-proprietary name (INN) or common name lusutrombopag Therapeutic area (MeSH) Thrombocytopenia Anatomical therapeutic chemical (ATC) code B02BX

### Pharmacotherapeutic group

Antihemorrhagics

### Therapeutic indication

Mulpleo is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures

## Authorisation details

EMA product number EMEA/H/C/004720 Marketing authorisation holder

Shionogi B.V.

Herengracht 464

Opinion adopted 13/12/2018 Marketing authorisation issued 18/02/2019 Revision 9

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Mulpleo : Procedural steps taken and scientific information after authorisation

English (EN) (153.07 KB - PDF)

**First published:** 29/08/2019

**Last updated:** 16/02/2024

[View](/en/documents/procedural-steps-after/mulpleo-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Lusutrombopag Shionogi : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/817852/2018

English (EN) (5.2 MB - PDF)

**First published:** 14/03/2019

[View](/en/documents/assessment-report/lusutrombopag-shionogi-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Lusutrombopag Shionogi

Adopted

Reference Number: EMA/CHMP/862586/2018

English (EN) (98.76 KB - PDF)

**First published:** 14/12/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-lusutrombopag-shionogi_en.pdf)

#### News on Mulpleo (previously Lusutrombopag Shionogi)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018) 14/12/2018

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 16/02/2024

## Share this page

[Back to top](#main-content)